Dabrafenib | List of Frontiers open access articles

Case Report

Published on 27 Apr 2026

Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: a case report

in Thoracic Oncology

Simran Chandra
Sagar Hansraj
Aakriti Adhikari
Ben Ponvilawan
Addison Tolentino
Dhruv Bansal

Frontiers in Oncology

doi 10.3389/fonc.2026.1795399

357 views

Original Research

Published on 11 Sep 2025

Impact of metabolic enzyme activity variability on dabrafenib disposition

in Drug Metabolism and Transport

Shi-yu Wang
Qing Chen
Zhong-xi Chen
Jing Chen
Jing Yuan
Li-shang Dai
Lian-guo Chen
Xiao-dan Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1643618

2,689 views

Case Report

Published on 07 May 2024

Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a BRAFV600E mutated high-grade glioma

in Neuro-Oncology and Neurosurgical Oncology

Barbara Castelli
Marco Tellini
Melina Guidi
Marco Di Nicola
Laura Giunti
Anna Maria Buccoliero
Maria Luigia Censullo
Alessandro Iacono
Isacco Desideri
Lorenzo Genitori

Frontiers in Oncology

doi 10.3389/fonc.2024.1359093

2,722 views
1 citation

Case Report

Published on 11 Jun 2021

Case Report: Vemurafenib Treatment in Brain Metastases of BRAFS365L-Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection

in Pharmacology of Anti-Cancer Drugs

Jianing Jiang
Jinqi Gao
Gang Wang
Jinyan Lv
Wenting Chen
Jing Ben
Ruoyu Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.688200

4,520 views
14 citations

Original Research

Published on 08 Apr 2021

GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells

in Cancer Molecular Targets and Therapeutics

Laurence Booth
Cameron West
Daniel Von Hoff
John M. Kirkwood
Paul Dent

Frontiers in Oncology

doi 10.3389/fonc.2021.656453

5,969 views
15 citations

Case Report

Published on 02 Dec 2022

Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor

in Breast Cancer

Alfonso López de Sá
Alicia de Luna
Mónica Antoñanzas
Vanesa García-Barberán
Fernando Moreno-Anton
Jose A. García-Sáenz

Frontiers in Oncology

doi 10.3389/fonc.2022.997346

5,791 views
4 citations

Case Report

Published on 21 Jul 2023

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Ruoxin Fang
Jun Gong
Zhengkai Liao

Frontiers in Oncology

doi 10.3389/fonc.2023.1220745

2,991 views
3 citations

Case Report

Published on 17 Mar 2026

BRAF class II-III mutations in NSCLC: a single center experience

in Thoracic Oncology

Sara Torresan
Martina Bortolot
Elisa Bertoli
Alessandro Del Conte
Brigida Stanzione
Elisa de Carlo
Monica Schiappacassi
Michele Spina
Gustavo Baldassarre
Alessandra Bearz

Frontiers in Oncology

doi 10.3389/fonc.2026.1717614

573 views

Brief Research Report

Published on 14 Feb 2023

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

in Skin Cancer

Walid Shalata
Rachel Steckbeck
Ilya Polishchuk
Ahron Yehonatan Cohen
Keren Rouvinov
Margarita Tokar
Ashraf Abu Jama
Omar Abu Saleh
Kim Sheva
Alexander Yakobson

Frontiers in Oncology

doi 10.3389/fonc.2023.1102330

3,456 views
4 citations

Case Report

Published on 05 Jan 2023

Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients

in Surgical Oncology

Xue Peng
Jianyong Lei
Zhihui Li
Kun Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.1099268

3,673 views
6 citations

Case Report

Published on 24 Nov 2025

Dabrafenib plus trametinib in an elderly patient with BRAF V600E-mutant advanced pancreatic adenocarcinoma: A case report

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Linger Liu
Xiaolian Zhu
Yinhong Guo
Mengyao Tang
Wu Zhou
Baisong Chen

Frontiers in Oncology

doi 10.3389/fonc.2025.1687796

1,469 views

Case Report

Published on 05 Apr 2019

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

in Cancer Molecular Targets and Therapeutics

Ernesto Rossi
Brigida Anna Maiorano
Monica Maria Pagliara
Maria Grazia Sammarco
Tommaso Dosa
Maurizio Martini
Guido Rindi
Emilio Bria
Maria Antonietta Blasi
Giampaolo Tortora

Frontiers in Oncology

doi 10.3389/fonc.2019.00232

6,251 views
47 citations

Case Report

Published on 05 Mar 2020

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report

in Pharmacology of Anti-Cancer Drugs

Marco Ghezzi
Andrea Garolla
Sabina Magagna
Iva Šabovich
Massimiliano Berretta
Carlo Foresta
Luca De Toni

Frontiers in Oncology

doi 10.3389/fonc.2020.00232

6,522 views
8 citations

Systematic Review

Published on 21 Apr 2022

Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis

in Skin Cancer

Ling Hong
Ping Huang
Xiaochun Zheng
Xiaolan Ye
Hongying Zhao
Jianwei Wang
Yanfei Shao

Frontiers in Oncology

doi 10.3389/fonc.2022.865656

5,054 views
2 citations

Case Report

Published on 06 Jan 2023

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review

in Pharmacology of Anti-Cancer Drugs

Simeng Zhang
Zichang Yang
Yu Cheng
Xiaoyu Guo
Chang Liu
Shuo Wang
Lingyun Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1019217

2,772 views
7 citations

Original Research

Published on 01 Apr 2025

New prognostic features and personalized treatment strategies of mitochondrial related genes in colorectal cancer patients

in Pharmacology of Anti-Cancer Drugs

Qizheng Xu
Zhiwen Wang
Shan-Tao Huang
Jia-Yu Shi
Yan Zhu
Han-Qing Pang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1540767

2,945 views
2 citations

Articles

Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: a case report

Impact of metabolic enzyme activity variability on dabrafenib disposition

Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a BRAFV600E mutated high-grade glioma

Case Report: Vemurafenib Treatment in Brain Metastases of BRAFS365L-Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection

GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells

Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review

BRAF class II-III mutations in NSCLC: a single center experience

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients

Dabrafenib plus trametinib in an elderly patient with BRAF V600E-mutant advanced pancreatic adenocarcinoma: A case report

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report

Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review

New prognostic features and personalized treatment strategies of mitochondrial related genes in colorectal cancer patients